Open access · CC-BY
via OpenAlex
Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis
Michael R. McClung, Nicholas C. Harvey, Lorraine A. Fitzpatrick, Paul D. Miller, Gary Hattersley, Yamei Wang, Felicia Cosman
Menopause The Journal of The North American Menopause Society · 2018 · ▲ 41 citations
Abstract
OBJECTIVE: Advanced age is an important risk factor for fracture. The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) trial showed that subcutaneous abaloparatide increased bone mineral density (BMD) and reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE. METHODS: Post hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial. RESULTS: The mean ages of the women ≥80 years were 81.9 and 81.7 years in the placebo (n = 43) and abaloparatide (n = 51) groups, respectively. The increases in BMD from baseline to 18 months with abaloparatide treatment were 3.9% at the total hip (P < 0.001), 3.6% at the femoral neck (P < 0.01), and 12.1% at the lumbar spine (P < 0.001), and were similar to those observed in the overall population. Abaloparatide therapy was associated with numerical, but not statistically significant, reductions in the risk of vertebral and nonvertebral fractures in this subpopulation, compared with placebo. The proportion of participants reporting adverse events was similar between treatment groups and between the older subgroup and the overall population. CONCLUSION: Abaloparatide was effective in increasing BMD in the very elderly subgroup of ACTIVE, with a safety profile similar to that of the overall study population.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1097/gme.0000000000001080
- Canonical
- link ↗
- Fetched
- 2026-10-18 MST
Cite this
APA
McClung, M.R., Harvey, N.C., Fitzpatrick, L.A., Miller, P.D., Hattersley, G., Wang, Y., & Cosman, F. (2018). Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. <em>Menopause The Journal of The North American Menopause Society</em>. https://doi.org/10.1097/gme.0000000000001080
Vancouver
McClung MR, Harvey NC, Fitzpatrick LA, Miller PD, Hattersley G, Wang Y, et al. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause The Journal of The North American Menopause Society. 2018. doi:10.1097/gme.0000000000001080.
BibTeX
@article{michael2018Effect,
title = {Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis},
author = {Michael R. McClung and Nicholas C. Harvey and Lorraine A. Fitzpatrick and Paul D. Miller and Gary Hattersley and Yamei Wang and Felicia Cosman},
journal = {Menopause The Journal of The North American Menopause Society},
year = {2018},
doi = {10.1097/gme.0000000000001080},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Bone and Mineral Research 2003
Citation only
The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis
Geriatrik Bilimler Dergisi 2026
Open access · CC-BY
Associations of Insulin Resistance Indices and Atherogenic Lipid Parameters with Bone Mineral Density and Fragility Fracture History in Men Aged 50 Years and Older and Postmenopausal Women with Osteopenia or Osteoporosis
The Journal of Clinical Endocrinology & Metabolism 2002
Open access · OA
Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis
Archives of Internal Medicine 2003
Citation only
Bone Mineral Density Measurement and Treatment for Osteoporosis in Older Individuals With Fractures
Geriatrics 2023
Open access · CC-BY
Can Leucine Supplementation Improve Frailty Index Scores?
Osteoporosis International 2006
Citation only